9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative)
Key Takeaways
Metastatic NSCLC management requires upfront broad-panel Next-Generation Sequencing (NGS) and PD-L1 immunohistochemistry to delineate actionable oncogenic driver alterations from driver-negative, biomarker-stratified disease prior to initiating first-line therapy.
For driver-negative non-squamous metastatic NSCLC with PD-L1 <50%, the standard frontline regimen is pembrolizumab plus carboplatin (or cisplatin) plus pemetrexed (KEYNOTE-189) with mandatory folic acid, vitamin B12, and dexamethasone premedication; squamous disease is treated with pembrolizumab plus carboplatin plus paclitaxel/nab-paclitaxel (KEYNOTE-407).
Osimertinib monotherapy (FLAURA) or osimertinib plus platinum/pemetrexed (FLAURA2) represents the frontline standard of care for classical EGFR-sensitizing mutations (Ex19del, L858R), demonstrating superior intracranial penetration and progression-free survival over 1st/2nd-generation TKIs.
Next-generation ALK/ROS1 inhibitors (alectinib, brigatinib, lorlatinib, repotrectinib) provide profound systemic and intracranial control; lorlatinib uniquely overcomes the G1202R solvent-front resistance mutation but requires clinical management of hyperlipidemia and neurocognitive toxicities.
Rare actionable driver alterations in NSCLC—including KRAS G12C (sotorasib, adagrasib), MET exon 14 skipping (capmatinib, tepotinib), RET fusions (selpercatinib, pralsetinib), BRAF V600E (dabrafenib + trametinib), and HER2 mutations (trastuzumab deruxtecan)—mandate target-specific oral kinase inhibitors or antibody-drug conjugates.
9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative)
Metastatic (Stage IV) Non-Small Cell Lung Cancer represents the archetype of modern precision oncology. Historically treated with empiric, palliative platinum-doublet cytotoxic regimens yielding a median overall survival (OS) of 8–10 months, Stage IV NSCLC is now stratified into distinct molecular and immunologic subsets. Management hinges upon comprehensive Next-Generation Sequencing (NGS) and PD-L1 immunohistochemistry (IHC) to match each patient with target-specific tyrosine kinase inhibitors (TKIs), antibody-drug conjugates (ADCs), or immune checkpoint inhibitor (ICI) combinations.
+-----------------------------------------------------------------------------+
| STAGE IV NSCLC INITIAL BIOMARKER TRIAGE |
| |
| [METASTATIC NSCLC CONFIRMED (HISTOLOGY: SQUAMOUS VS NON-SQUAMOUS)] |
| | |
| v |
| [MANDATORY COMPREHENSIVE BIOMARKER PROFILING (TISSUE NGS + ctDNA + IHC)] |
| - Actionable Driver Oncogenes: EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, |
| MET ex14 skip, RET, NTRK1/2/3, ERBB2 (HER2) |
| - Immunologic Biomarkers: PD-L1 Tumor Proportion Score (TPS: 22C3/SP263) |
| | |
| +-------------------------+-------------------------+ |
| | | |
| v v |
| [ACTIONABLE DRIVER IDENTIFIED] [DRIVER NEGATIVE / WT] |
| Initiate First-Line Targeted TKI Stratify by PD-L1 TPS & |
| (e.g., Osimertinib, Alectinib, Histology (Squamous vs |
| Selpercatinib, Capmatinib) Non-Squamous) |
| *AVOID FRONT-LINE IMMUNOTHERAPY* *CHEMOIMMUNOTHERAPY / ICI* |
+-----------------------------------------------------------------------------+
Important
Critical Practice Standard: Biomarker Turnaround & Immunotherapy Gating Immune checkpoint inhibitors (single-agent pembrolizumab, atezolizumab, or chemoimmunotherapy) demonstrate exceedingly poor response rates in patients with classic driver oncogenes (EGFR mutations, ALK fusions, ROS1 fusions), despite high PD-L1 expression. Furthermore, administering PD-1/PD-L1 inhibitors immediately prior to starting EGFR or ALK TKIs significantly increases the risk of severe, life-threatening immune-mediated hepatotoxicity and interstitial lung disease (ILD). Clinicians must wait for NGS results before committing to frontline immunotherapy.
1. Driver-Negative Metastatic NSCLC: Biomarker-Directed Frontline Algorithms
For patients without actionable driver alterations, treatment selection is governed by PD-L1 Tumor Proportion Score (TPS) and histologic subtype (Non-Squamous vs. Squamous).
+-----------------------------------------------------------------------------+
| DRIVER-NEGATIVE FRONTLINE TREATMENT ALGORITHM |
| |
| [PD-L1 TUMOR PROPORTION SCORE (TPS)] |
| | |
| +---------------------------+---------------------------+ |
| | | |
| v v |
| [PD-L1 HIGH: TPS >= 50%] [PD-L1 < 50% OR |
| - Single-Agent Immunotherapy: HIGH TUMOR BURDEN] |
| * Pembrolizumab 200 mg Q3W (KEYNOTE-024) | |
| * Atezolizumab 1200 mg Q3W (IMpower110) | |
| * Cemiplimab 350 mg Q3W (EMPOWER-Lung 1) | |
| - (Chemoimmunotherapy preferred if high | |
| symptom burden or visceral crisis) | |
| | |
| +-------------------------------------------------------+ |
| | |
| v |
| [HISTOLOGY STRATIFICATION] |
| | |
| +---------------------------+ |
| | | |
| v v |
| [NON-SQUAMOUS HISTOLOGY] [SQUAMOUS HISTOLOGY] |
| - Pembrolizumab + - Pembrolizumab + |
| Carboplatin/Cisplatin + Carboplatin + |
| Pemetrexed (KEYNOTE-189) Paclitaxel / Nab-Paclitaxel (KEYNOTE-407) |
| - ABCP Quadruplet: - Nivolumab + Ipilimumab + |
| Atezolizumab + Bevacizumab+ 2c Platinum Doublet (CheckMate 9LA) |
| Carboplatin + Paclitaxel - Cemiplimab + Platinum Doublet |
| (IMpower150) |
+-----------------------------------------------------------------------------+
Landmark Frontline Chemoimmunotherapy Trials
- KEYNOTE-189 (Non-Squamous NSCLC): Double-blind Phase 3 trial comparing pembrolizumab (200 mg Q3W) + pemetrexed (500 mg/m2) + carboplatin (AUC 5) / cisplatin (75 mg/m2) x 4 cycles followed by maintenance pembrolizumab + pemetrexed versus chemotherapy alone. Pembrolizumab combination demonstrated a striking doubling in median overall survival (22.0 vs. 10.7 months; HR 0.56, p < 0.001) and significant PFS improvement across all PD-L1 strata (<1%, 1–49%, >=50%).
- KEYNOTE-407 (Squamous NSCLC): Phase 3 trial in metastatic squamous NSCLC evaluating pembrolizumab (200 mg Q3W) + carboplatin (AUC 6) + paclitaxel (200 mg/m2) or nab-paclitaxel (100 mg/m2 weekly) x 4 cycles followed by maintenance pembrolizumab. Demonstrates superior median OS (17.1 vs. 11.6 months; HR 0.71) and PFS.
- IMpower150 (ABCP Quadruplet in Non-Squamous): Evaluated atezolizumab + bevacizumab + carboplatin + paclitaxel (ABCP) vs. BCP. Demonstrates survival advantage (mOS 19.5 vs 14.7 mo; HR 0.78), showing unique activity in patients with baseline liver metastases and sensitizing EGFR mutations progressing after TKIs.
- CheckMate 9LA (Dual Checkpoint + 2 Chemotherapy Cycles): Nivolumab (360 mg Q3W) + ipilimumab (1 mg/kg Q6W) + 2 cycles of histology-directed platinum doublet chemotherapy demonstrated superior OS over 4 cycles of chemotherapy alone (mOS 15.6 vs 10.9 months; HR 0.72).
Comprehensive Pemetrexed Supportive Care Protocol
+-----------------------------------------------------------------------------+
| CLINICAL PHARMACIST PEMETREXED PREMEDICATION PROTOCOL |
| |
| 1. FOLIC ACID SUPPLEMENTATION (Mandatory to prevent fatal myelosuppression)|
| - Dose: 400 mcg to 1000 mcg PO ONCE DAILY |
| - Timing: Must begin at least 7 DAYS PRIOR to Cycle 1 Day 1 |
| - Duration: Continue daily throughout treatment and for 21 DAYS after |
| the final pemetrexed dose. |
| |
| 2. VITAMIN B12 SUPPLEMENTATION (Protects against mucosal / hematologic tox)|
| - Dose: 1000 mcg (1 mg) INTRAMUSCULAR INJECTION |
| - Timing: First injection administered within 7 DAYS PRIOR to Cycle 1 |
| - Maintenance: Repeat once EVERY 3 CYCLES (approx. every 9-12 weeks) |
| |
| 3. DEXAMETHASONE CUTANEOUS PROPHYLAXIS (Prevents severe erythematous rash) |
| - Dose: 4 mg PO TWICE DAILY (BID) for 3 consecutive days: |
| * Day -1 (the day before pemetrexed) |
| * Day 0 (the day of pemetrexed administration) |
| * Day +1 (the day following pemetrexed) |
| |
| 4. RENAL FUNCTION CUTOFF & NSAID AVOIDANCE: |
| - Absolute Cutoff: Pemetrexed is CONTRAINDICATED if CrCl < 45 mL/min |
| - NSAID Interactions: If CrCl is 45-79 mL/min, hold short-acting NSAIDs|
| (ibuprofen) for 2 days before, day of, and 2 days after pemetrexed; |
| hold long-acting NSAIDs (naproxen, meloxicam) for 5 days before. |
+-----------------------------------------------------------------------------+
Bevacizumab Safety Precautions & Absolute Contraindications
- Histology Restriction: Bevacizumab is strictly restricted to non-squamous histology. In squamous NSCLC, VEGF inhibition causes central cavitary tumor necrosis, resulting in life-threatening or fatal pulmonary hemorrhage/hemoptysis.
- Absolute Contraindications: Active hemoptysis (>=2.5 mL of red blood), central cavitary tumors abutting major mediastinal vessels, uncontrolled severe hypertension, active gastrointestinal perforation/fistulae, and major surgery within 28 days (hold bevacizumab >=4–6 weeks before and after elective surgeries due to wound dehiscence).
2. Master Oncogenic Driver Target Profiling & Precision Therapeutics
+-----------------------------------------------------------------------------+
| ACTIONABLE ONCOGENIC DRIVER LANDSCAPE IN NSCLC |
| |
| [EGFR (15-20%)] ---> Ex19del / L858R: Osimertinib (FLAURA/FLAURA2) |
| ---> Exon 20 Ins: Amivantamab + Chemo (PAPILLON) |
| |
| [ALK (4-5%)] ---> Alectinib, Brigatinib, Lorlatinib (CROWN) |
| |
| [ROS1 (1-2%)] ---> Entrectinib, Repotrectinib, Crizotinib |
| |
| [BRAF (2-4%)] ---> V600E: Dabrafenib + Trametinib; Encorafenib + Bini |
| |
| [KRAS (25-30%)] ---> G12C (13%): Sotorasib, Adagrasib (2nd-Line) |
| |
| [MET (3-4%)] ---> Exon 14 Skipping: Capmatinib, Tepotinib |
| |
| [RET (1-2%)] ---> Selpercatinib, Pralsetinib |
| |
| [HER2 (2-3%)] ---> ERBB2 Activating Mutation: Trastuzumab deruxtecan |
| |
| [NTRK (0.2%)] ---> Fusions (NTRK1-3): Larotrectinib, Entrectinib |
+-----------------------------------------------------------------------------+
Comprehensive Master Matrix of Targeted Kinase Inhibitors & ADCs in NSCLC
| Biomarker Alteration | Preferred Frontline Agent(s) | Mechanism of Action | Standard Dosing & Schedule | Signature Toxicities & Monitoring Pearls |
|---|---|---|---|---|
| EGFR Classic (Ex19del, L858R) | Osimertinib | 3rd-generation irreversible mutant-selective TKI (Cys797 covalent binding) | 80 mg PO daily (with or without food) | QTc prolongation, LVEF reduction (cardiomyopathy), ILD/pneumonitis (2–4%), cytopenias, stomatitis. Spares wild-type EGFR (minimal skin toxicity). |
| EGFR Exon 20 Insertions | Amivantamab + Chemo | Fully human bispecific EGFR-MET antibody directed to extracellular domains | Amivantamab IV weekly x 4 weeks, then Q2W + Carboplatin/Pemetrexed | High rate of infusion-related reactions (IRRs in 65% on Day 1; mandatory split dosing D1/D2 and premedication with antihistamine, antipyretic, dexamethasone), rash, paronychia. |
| ALK Rearrangements | Alectinib (or Lorlatinib, Brigatinib) | Potent, brain-penetrant next-generation ALK/RET TKI | 600 mg PO BID with food | Elevated CPK/myalgia (monitor CPK Q2W for month 1), bradycardia, photosensitivity, elevated bilirubin. |
| ALK (High CNS / Resistance) | Lorlatinib | 3rd-generation compact macrocyclic ALK/ROS1 TKI (active vs. G1202R) | 100 mg PO daily | Severe hypercholesterolemia (80%) and hypertriglyceridemia (60%) -> start statin (rosuvastatin). Central neurocognitive/mood toxicities (hallucinations, cognitive slowing). |
| ROS1 Fusions | Entrectinib (or Repotrectinib, Crizotinib) | CNS-active ROS1 and TRK A/B/C tyrosine kinase inhibitor | 600 mg PO daily with or without food | Weight gain, dizziness/ataxia, paresthesias, hyperuricemia, cognitive changes, QTc prolongation, bone fracture risk. |
| BRAF V600E | Dabrafenib + Trametinib | BRAF monomer inhibitor + MEK1/2 allosteric inhibitor | Dabrafenib 150 mg PO BID + Trametinib 2 mg PO daily (empty stomach) | Pyrexia syndrome (55%): hold dabrafenib at >=38.5°C; resume upon resolution. Trametinib requires refrigeration (2–8°C). Serous retinopathy (RPED), LVEF decline. |
| KRAS G12C | Sotorasib (or Adagrasib) | Small-molecule covalent inhibitor binding the switch II pocket of GDP-bound KRAS(G12C) | Sotorasib 960 mg PO daily OR Adagrasib 600 mg PO BID | Sotorasib: Hepatotoxicity (AST/ALT elevation in 15–20%), diarrhea. Adagrasib: QTc prolongation, GI toxicity, potent CYP3A4 inhibitor/substrate. Used >=2nd line. |
| MET Exon 14 Skipping | Capmatinib (or Tepotinib) | Highly selective ATP-competitive type Ib MET kinase inhibitor | Capmatinib 400 mg PO BID OR Tepotinib 450 mg PO daily | Peripheral edema (50–60%): manage with elevation and compression (loop diuretics ineffective). Asymptomatic serum creatinine elevation via renal transporter (MATE1/OCT2) inhibition. |
| RET Fusions | Selpercatinib (or Pralsetinib) | Highly selective, CNS-active small-molecule RET kinase inhibitor | Selpercatinib 160 mg PO BID (or weight-tiered) | Secondary hypertension, transaminitis, QTc prolongation, dry mouth, hemorrhagic events, hypersensitivity reactions (fever, rash). |
| HER2 (ERBB2) Mutations | Trastuzumab deruxtecan (T-DXd) | HER2-directed antibody-drug conjugate with topoisomerase I inhibitor exatecan payload | 5.4 mg/kg IV Q3W | Boxed Warning for Interstitial Lung Disease (ILD/pneumonitis) in 12–15%; immediately hold for Grade 1 and permanently discontinue for Grade >=2. LVEF decrease, alopecia, severe nausea/emesis (moderate emetic risk). |
| NTRK 1/2/3 Fusions | Larotrectinib (or Entrectinib) | Highly selective pan-TRK kinase inhibitor (TRKA, TRKB, TRKC) | Larotrectinib 100 mg PO BID (capsule or oral solution) | Neurocognitive changes, dizziness, ataxia, rapid weight gain/hyperphagia, rebound withdrawal pain following sudden treatment cessation. |
3. Mechanisms of Acquired Resistance and Post-Progression Strategies
+-----------------------------------------------------------------------------+
| OSIMERTINIB RESISTANCE MECHANISMS & SECOND-LINE |
| |
| [OSIMERTINIB RESISTANCE EMERGENCE] |
| | |
| v |
| [REPEAT TISSUE / LIQUID BIOPSY NGS] |
| | |
| +---------------------------+---------------------------+ |
| | | | |
| v v v |
| [ON-TARGET TERTIARY] [OFF-TARGET BYPASS] [HISTOLOGIC SHIFT] |
| - EGFR C797S Mutation - MET Amplification (15-25%) - Transformation |
| * If in trans with T790M: * Osimertinib + to Small Cell |
| 1st-gen + Osimertinib Savolitinib / Amivantamab Lung Cancer |
| * If in cis with T790M: - HER2 Amplification (5%) (SCLC) (~5-10%) |
| Chemo / ADC * Trastuzumab deruxtecan * Treat with |
| - EGFR Exon 20 Mutations - BRAF V600E / RET / ALK Platinum + |
| * Amivantamab + Chemo * Matched targeted therapy Etoposide |
+-----------------------------------------------------------------------------+
Overcoming Resistance in ALK-Rearranged NSCLC
- Following first-line alectinib or brigatinib progression, repeat molecular profiling frequently reveals the ALK G1202R solvent-front mutation (~30–40% of secondary resistance). The bulky positively charged arginine side chain sterically clashes with 1st/2nd-generation ALK inhibitors.
- Lorlatinib is uniquely structurally configured as a compact, rigid macrocycle that fits into the kinase binding cleft despite the bulky G1202R mutation, producing objective response rates >40–50% and median PFS >6–9 months in alectinib-refractory disease.
4. Second-Line Driver-Negative Chemotherapy & Anti-Angiogenic Regimens
When driver-negative patients experience disease progression on frontline chemoimmunotherapy, standard second-line options include:
- Docetaxel + Ramucirumab (REVEL Trial): Docetaxel (75 mg/m2 IV Day 1) plus the VEGFR2 monoclonal antibody ramucirumab (10 mg/kg IV Day 1) every 21 days demonstrated a statistically significant OS improvement over docetaxel alone (median OS 10.5 vs. 9.1 months; HR 0.86, p = 0.023). Toxicities: neutropenia, febrile neutropenia (G-CSF primary prophylaxis recommended), hypertension, bleeding, stomatitis.
- Single-Agent Docetaxel: 75 mg/m2 IV Q21D with dexamethasone premedication.
- Pemetrexed Monotherapy: 500 mg/m2 IV Q21D (if non-squamous and not previously administered during frontline therapy).
A 67-year-old male is diagnosed with Stage IV metastatic lung adenocarcinoma. Molecular NGS testing confirms absence of EGFR, ALK, ROS1, BRAF, RET, MET, and KRAS driver alterations. PD-L1 IHC testing reveals a Tumor Proportion Score (TPS) of 0%. His baseline serum creatinine is 0.9 mg/dL (calculated CrCl 78 mL/min). The medical oncologist prescribes first-line therapy with carboplatin (AUC 5), pemetrexed (500 mg/m2), and pembrolizumab (200 mg) every 21 days (KEYNOTE-189 protocol). Which of the following supportive care regimens is mandatory to prevent severe, potentially life-threatening hematologic toxicity from pemetrexed?
Initiate oral folic acid (400–1000 mcg daily) starting at least 7 days before Cycle 1 and continuing throughout treatment plus intramuscular vitamin B12 (1000 mcg) every 9 weeks.
Administer intravenous rasburicase 0.2 mg/kg 2 hours prior to every pemetrexed infusion to prevent acute urate nephropathy.
Initiate oral leucovorin calcium 25 mg every 6 hours for 12 doses starting exactly 24 hours after each pemetrexed infusion.
Administer prophylactic mesna at 20% of the carboplatin dose to prevent chemical hemorrhagic cystitis.
A 54-year-old female with newly diagnosed metastatic lung adenocarcinoma presents with symptomatic bilateral pulmonary metastases and multiple osteolytic spinal lesions. Comprehensive NGS testing reveals an ALK-EML4 gene rearrangement. Brain MRI demonstrates three asymptomatic intracranial metastases (largest measuring 6 mm). Which of the following represents the most appropriate, guideline-recommended frontline systemic therapy?
Initiate upfront platinum-doublet chemotherapy plus pembrolizumab and schedule immediate whole-brain radiation therapy (WBRT).
Initiate alectinib 600 mg orally twice daily with food.
Initiate crizotinib 250 mg orally twice daily and initiate omeprazole 20 mg daily for gastric protection.
Initiate sotorasib 960 mg orally daily combined with stereotactic radiosurgery.
A 62-year-old patient with metastatic ALK-rearranged NSCLC experiences systemic and intracranial disease progression after 28 months of initial disease control on first-line alectinib. Repeat molecular profiling from a newly progressing liver metastasis identifies the emergence of the secondary ALK G1202R solvent-front resistance mutation. Which of the following small-molecule inhibitors is specifically engineered to overcome this resistance mutation, and what signature toxicities require proactive clinical monitoring?
Crizotinib; monitor for QTc prolongation and photopsia trails of light.
Ceritinib; monitor for severe Grade 3/4 diarrhea and pancreatitis.
Lorlatinib; monitor for severe hypercholesterolemia, hypertriglyceridemia, and central neurocognitive/mood changes.
Capmatinib; monitor for peripheral lower extremity edema and serum creatinine elevation.
A 58-year-old non-smoking female with metastatic lung adenocarcinoma undergoes NGS profiling which reveals an activating HER2 (ERBB2) exon 20 insertion mutation. She experiences disease progression after 4 cycles of carboplatin and pemetrexed. Which of the following targeted agents is FDA-approved for this specific genomic alteration, and what is its most critical boxed warning?
Ado-trastuzumab emtansine (T-DM1); boxed warning for hepatotoxicity and embryo-fetal toxicity.
Sotorasib; boxed warning for acute fulminant hepatic necrosis.
Selpercatinib; boxed warning for severe secondary hypertensive crisis and cerebral hemorrhage.
Trastuzumab deruxtecan (T-DXd); boxed warning for drug-induced interstitial lung disease (ILD) / pneumonitis.
Sections you finish are checked off in the contents.